Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.

CompletedOBSERVATIONAL
Enrollment

756

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

June 18, 2023

Study Completion Date

December 18, 2023

Conditions
SARS-CoV InfectionCovid19
Interventions
OTHER

biobank

"* Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~* For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~* Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~* Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5"

Trial Locations (37)

33076

CHU de Bordeaux, Bordeaux

54511

CHRU de Nancy, Nancy

75010

Hôpital Lariboisière - SMIT, Paris

75012

Hôpital Saint Antoine, Paris

75018

Hôpital Bichat Claude-Bernard, Paris

75020

Hôpital Tenon, Paris

91106

Centre Hospitalier Sud Francilien - Hématologie, Corbeil-Essonnes

Centre Hospitalier Sud Francilien - Néphrologie, Corbeil-Essonnes

94275

Hôpital Bicêtre - Médecine interne, Le Kremlin-Bicêtre

Hôpital Bicêtre - SMIT, Le Kremlin-Bicêtre

97261

CHU de Martinique, Fort-de-France

Unknown

CH Agen-Nerac, Agen

CHU d'Angers, Angers

CHR Metz-Thionville, Ars-Laquenexy

Hôpital Avicenne, Bobigny

CHU Gabriel Montpied, Clermont-Ferrand

CHU de Dijon, Dijon

CHU de Limoges, Limoges

Hospices Civils de Lyon (HCL), Lyon

CHU de Montpellier, Montpellier

CHU de Nantes, Nantes

CHU de Nîmes, Nîmes

Hôpital Bichat Claude-Bernard - SAU, Paris

Hôpital Lariboisière - SAU SMUR, Paris

Hôpital Pitié-Salpêtrière, Paris

Hôpital Saint Antoine - SAU, Paris

Hôpital Saint-Louis, Paris

Hôpital Universitaire Necker Enfants Malades, Paris

Hôpitaux Cochin - Port Royal, Paris

CHI Poissy St Germain en Laye, Poissy

CHU de Poitiers, Poitiers

CHU de Rennes, Rennes

CH de Tarbes, Tarbes

CHU de Toulouse - IUCT - Oncopole, Toulouse

CHU de Toulouse, Toulouse

CH de Tourcoing, Tourcoing

CHRU de Tours - Hôpital Bretonneau, Tours

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT04885452 - Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort. | Biotech Hunter | Biotech Hunter